Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409435 · ClinicalTrials.gov registry record · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
A Phase 2 study of Postural Tachycardia Syndrome, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00409435: Recruiting Phase 2 study of Postural Tachycardia Syndrome, sponsored by Mayo Clinic.
NCT00409435 is a Phase 2 study of Postural Tachycardia Syndrome that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 80-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00409435, a Phase 2 study of Postural Tachycardia Syndrome, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG pyridostigmine
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-10 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT00409435 shows while recruiting
NCT00409435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 80-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Postural Tachycardia Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00409435 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00409435 about?
NCT00409435 is a clinical study titled "A Study of Pyridostigmine in Postural Tachycardia Syndrome". This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
What is the current status of trial NCT00409435?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-10. Estimated completion is 2027-02.
What conditions does trial NCT00409435 study?
This clinical trial studies the following conditions: Postural Tachycardia Syndrome.
What interventions are being tested in trial NCT00409435?
The interventions under investigation include: Placebo (DRUG), pyridostigmine (DRUG).
Who is sponsoring clinical trial NCT00409435?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00409435 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postural Tachycardia Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00409435's enrollment target sits among peer trials
50 8th of 19 higher than 12 of 19 other Postural Tachycardia Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postural Tachycardia Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?
RECRUITING · NA
-
Inappropriate Sinus Tachycardia Registry
RECRUITING
-
Autoimmune Basis for Postural Tachycardia Syndrome
RECRUITING · NA
-
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
ACTIVE NOT RECRUITING · NA
-
Acute Salt Handling in Orthostatic Intolerance
ACTIVE NOT RECRUITING · NA
-
POTS NET mRNA Functional Correlation With NET Activity
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia